SG11201407682TA - Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators - Google Patents
Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulatorsInfo
- Publication number
- SG11201407682TA SG11201407682TA SG11201407682TA SG11201407682TA SG11201407682TA SG 11201407682T A SG11201407682T A SG 11201407682TA SG 11201407682T A SG11201407682T A SG 11201407682TA SG 11201407682T A SG11201407682T A SG 11201407682TA SG 11201407682T A SG11201407682T A SG 11201407682TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- receptor modulators
- glucocorticoid receptor
- heteroaryl
- fused azadecalin
- Prior art date
Links
- 229940117965 Glucocorticoid receptor modulator Drugs 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 235000001543 Corylus americana Nutrition 0.000 abstract 1
- 240000007582 Corylus avellana Species 0.000 abstract 1
- 235000007466 Corylus avellana Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- -1 heteroaryl ketone Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Electroluminescent Light Sources (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651669P | 2012-05-25 | 2012-05-25 | |
| US201261691083P | 2012-08-20 | 2012-08-20 | |
| US201261715907P | 2012-10-19 | 2012-10-19 | |
| US201361759520P | 2013-02-01 | 2013-02-01 | |
| US201361781629P | 2013-03-14 | 2013-03-14 | |
| PCT/US2013/042732 WO2013177559A2 (en) | 2012-05-25 | 2013-05-24 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407682TA true SG11201407682TA (en) | 2014-12-30 |
Family
ID=49624542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407682TA SG11201407682TA (en) | 2012-05-25 | 2013-05-24 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
Country Status (23)
| Country | Link |
|---|---|
| EP (6) | EP3851107B1 (he) |
| JP (1) | JP6172871B2 (he) |
| KR (1) | KR102062640B1 (he) |
| CN (1) | CN104619328B (he) |
| AU (1) | AU2013266110C1 (he) |
| BR (1) | BR112014028857B1 (he) |
| CA (1) | CA2872260C (he) |
| CL (1) | CL2014003173A1 (he) |
| DK (4) | DK3590517T3 (he) |
| ES (4) | ES2873949T3 (he) |
| HK (2) | HK1208818A1 (he) |
| IL (1) | IL235868A (he) |
| MX (1) | MX365423B (he) |
| MY (1) | MY172739A (he) |
| NZ (1) | NZ701469A (he) |
| PE (1) | PE20150352A1 (he) |
| PH (1) | PH12014502584B1 (he) |
| PL (4) | PL3338781T3 (he) |
| PT (4) | PT3590517T (he) |
| RU (1) | RU2639867C2 (he) |
| SG (1) | SG11201407682TA (he) |
| WO (1) | WO2013177559A2 (he) |
| ZA (1) | ZA201408182B (he) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| EP3848027B1 (en) | 2013-11-25 | 2023-04-05 | Corcept Therapeutics Incorporated | Octahydro fused azadecalin glucocorticoid receptor modulators |
| EP3265127B1 (en) * | 2015-03-02 | 2024-02-21 | Corcept Therapeutics, Inc. | Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor |
| MX2017011885A (es) * | 2015-03-30 | 2018-02-19 | Corcept Therapeutics Inc | Uso de antagonistas de receptores de glucocorticoides en combinacion con glucocorticoides para tratar la insuficiencia adrenal. |
| MX2017014857A (es) | 2015-05-18 | 2018-08-15 | Corcept Therapeutics Inc | Metodos para diagnosticar y evaluar tratamiento para sindrome de cushing. |
| ES2865334T3 (es) | 2015-08-13 | 2021-10-15 | Corcept Therapeutics Inc | Método de diagnóstico diferencial de síndrome de Cushing dependiente de ACTH |
| IL297201A (he) * | 2016-03-01 | 2022-12-01 | Corcept Therapeutics Inc | שימוש במודולטורים של קולטני גלוקוקורטיקואידים להגברת פעילות של מעכבי checkpoint |
| US9943505B2 (en) * | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
| EP3600282A4 (en) * | 2017-03-31 | 2020-08-19 | Corcept Therapeutics, Inc. | GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF COLD CANCER |
| CA3065555A1 (en) * | 2017-06-20 | 2018-12-27 | Corcept Therapeutics, Inc. | Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators |
| WO2019209693A1 (en) * | 2018-04-23 | 2019-10-31 | Corcept Therapeutics, Inc. | Methods of preparing regioselective n-alkyl triazoles |
| US10946005B2 (en) * | 2018-11-09 | 2021-03-16 | Corcept Therapeutics Incorporated | Methods for shrinking pituitary tumors |
| US11389432B2 (en) | 2018-12-19 | 2022-07-19 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| KR102657097B1 (ko) | 2018-12-19 | 2024-04-15 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 헤테로아릴-케톤 융합 아자데칼린 화합물인 렐라코릴란트를 함유하는 약학적 제제 |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| AU2019405771A1 (en) * | 2018-12-20 | 2021-06-17 | Corcept Therapeutics Incorporated | Methods for imaging and treatment of somatostatin-receptor positive tumors |
| KR20210118971A (ko) | 2019-02-22 | 2021-10-01 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 헤테로아릴-케톤 융합 아자데칼린 글루코코르티코이드 수용체 조절제인 렐라코릴란트의 치료 용도 |
| CA3158112A1 (en) * | 2019-10-16 | 2021-04-22 | Corcept Therapeutics Incorporated | Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist |
| EP4072556A4 (en) | 2019-12-11 | 2024-01-03 | Corcept Therapeutics Incorporated | METHOD FOR TREATING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN WITH MIRICORILANT |
| EP4076470A4 (en) | 2019-12-21 | 2023-11-22 | Corcept Therapeutics Incorporated | DIFFERENTIAL TREATMENT AND DIAGNOSIS BETWEEN ACTH-DEPENDENT CUSHING SYNDROME AND ACTH-INDEPENDENT CUSHING SYNDROME |
| WO2022134033A1 (en) * | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| CN116829556A (zh) * | 2021-02-03 | 2023-09-29 | 江苏恒瑞医药股份有限公司 | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 |
| WO2024077169A1 (en) * | 2022-10-06 | 2024-04-11 | Corcept Therapeutics Incorporated | Formulations of glucocorticoid receptor modulators |
| WO2024173745A1 (en) * | 2023-02-17 | 2024-08-22 | Corcept Therapeutics Incorporated | Methods and compositions for treating huntington's disease and its symptoms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| GB8828669D0 (en) | 1988-12-08 | 1989-01-11 | Lilly Industries Ltd | Organic compounds |
| AU2005222421B2 (en) | 2004-03-09 | 2010-09-23 | Corcept Therapeutics, Inc. | Fused ring azadecalin glucocorticoid receptor modulators |
| US7640389B2 (en) * | 2006-02-28 | 2009-12-29 | Freescale Semiconductor, Inc. | Non-volatile memory having a multiple block erase mode and method therefor |
| EP1932843A1 (en) * | 2006-12-14 | 2008-06-18 | sanofi-aventis | Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals |
| AU2011293193A1 (en) | 2010-08-27 | 2013-02-14 | Corcept Therapeutics, Inc. | Pyridyl-amine fused azadecalin modulators |
-
2013
- 2013-05-24 PL PL18154256T patent/PL3338781T3/pl unknown
- 2013-05-24 PT PT191888858T patent/PT3590517T/pt unknown
- 2013-05-24 DK DK19188885.8T patent/DK3590517T3/da active
- 2013-05-24 PL PL19188885T patent/PL3590517T3/pl unknown
- 2013-05-24 WO PCT/US2013/042732 patent/WO2013177559A2/en active Application Filing
- 2013-05-24 ES ES19188885T patent/ES2873949T3/es active Active
- 2013-05-24 EP EP21154665.0A patent/EP3851107B1/en active Active
- 2013-05-24 KR KR1020147036405A patent/KR102062640B1/ko active IP Right Grant
- 2013-05-24 MY MYPI2014003289A patent/MY172739A/en unknown
- 2013-05-24 EP EP13793417.0A patent/EP2854814B1/en active Active
- 2013-05-24 EP EP24192650.0A patent/EP4434584A2/en active Pending
- 2013-05-24 PE PE2014002054A patent/PE20150352A1/es active IP Right Grant
- 2013-05-24 EP EP19188885.8A patent/EP3590517B1/en active Active
- 2013-05-24 PT PT137934170T patent/PT2854814T/pt unknown
- 2013-05-24 PT PT211546650T patent/PT3851107T/pt unknown
- 2013-05-24 MX MX2014014239A patent/MX365423B/es active IP Right Grant
- 2013-05-24 ES ES18154256T patent/ES2753816T3/es active Active
- 2013-05-24 SG SG11201407682TA patent/SG11201407682TA/en unknown
- 2013-05-24 PT PT181542564T patent/PT3338781T/pt unknown
- 2013-05-24 RU RU2014152625A patent/RU2639867C2/ru active
- 2013-05-24 DK DK21154665.0T patent/DK3851107T3/da active
- 2013-05-24 PL PL21154665.0T patent/PL3851107T3/pl unknown
- 2013-05-24 DK DK13793417.0T patent/DK2854814T3/en active
- 2013-05-24 JP JP2015514233A patent/JP6172871B2/ja active Active
- 2013-05-24 EP EP18154256.4A patent/EP3338781B1/en active Active
- 2013-05-24 DK DK18154256T patent/DK3338781T3/da active
- 2013-05-24 NZ NZ701469A patent/NZ701469A/en unknown
- 2013-05-24 ES ES13793417.0T patent/ES2665338T3/es active Active
- 2013-05-24 AU AU2013266110A patent/AU2013266110C1/en active Active
- 2013-05-24 ES ES21154665T patent/ES2930298T3/es active Active
- 2013-05-24 PL PL13793417T patent/PL2854814T3/pl unknown
- 2013-05-24 EP EP22193438.3A patent/EP4119561B1/en active Active
- 2013-05-24 CA CA2872260A patent/CA2872260C/en active Active
- 2013-05-24 CN CN201380039218.1A patent/CN104619328B/zh active Active
- 2013-05-24 BR BR112014028857-7A patent/BR112014028857B1/pt active IP Right Grant
-
2014
- 2014-11-10 ZA ZA2014/08182A patent/ZA201408182B/en unknown
- 2014-11-19 PH PH12014502584A patent/PH12014502584B1/en unknown
- 2014-11-21 CL CL2014003173A patent/CL2014003173A1/es unknown
- 2014-11-23 IL IL235868A patent/IL235868A/he active IP Right Grant
-
2015
- 2015-09-29 HK HK15109587.3A patent/HK1208818A1/xx unknown
-
2018
- 2018-07-23 HK HK18109510.2A patent/HK1250014B/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407682TA (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
| SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201407900WA (en) | Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| SG11201804162WA (en) | Compositions comprising bacterial strains | |
| SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201407981RA (en) | Compositions comprising an anti-pdgf aptamer and a vegf antagonist | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201408261UA (en) | Syringe | |
| SG11201408232RA (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201407372UA (en) | Nampt inhibitors | |
| SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| SG11201811149TA (en) | METABOLIC DRUG LOADING OF EVs | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201407710VA (en) | Compositions comprising short-acting benzodiazepines | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201908929VA (en) | Synthekine compositions and methods of use |